Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Debt Repayments (2016 - 2019)

Enanta Pharmaceuticals (ENTA) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $22000.0 as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Long-Term Debt Repayments rose 10.0% year-over-year to $22000.0, compared with a TTM value of $86000.0 through Sep 2019, up 8.86%, and an annual FY2019 reading of $86000.0, up 8.86% over the prior year.
  • Long-Term Debt Repayments was $22000.0 for Q3 2019 at Enanta Pharmaceuticals, roughly flat from $22000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $22000.0 in Q2 2019 and bottomed at $16000.0 in Q4 2015.
  • Average Long-Term Debt Repayments over 5 years is $19125.0, with a median of $19000.0 recorded in 2017.
  • The sharpest move saw Long-Term Debt Repayments rose 12.5% in 2016, then grew 5.0% in 2019.
  • Year by year, Long-Term Debt Repayments stood at $16000.0 in 2015, then grew by 12.5% to $18000.0 in 2016, then increased by 5.56% to $19000.0 in 2017, then grew by 10.53% to $21000.0 in 2018, then increased by 4.76% to $22000.0 in 2019.
  • Business Quant data shows Long-Term Debt Repayments for ENTA at $22000.0 in Q3 2019, $22000.0 in Q2 2019, and $21000.0 in Q1 2019.